Drug and Therapeutics Bulletin 2002;40:70-72; doi:10.1136/dtb.2002.40970
Copyright © 2002 by the BMJ Publishing Group Ltd.
SSRIs for premenstrual dysphoric disorder
Relevant BNF section: 4.3.3
Around 2-10% of women have premenstrual symptoms that severely disrupt daily living.1–3 When such symptoms are dominated by severe disturbances of mood and behaviour, the condition has been named premenstrual dysphoric disorder (PMDD).4 Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI), is licensed in the UK for the treatment of PMDD. Here, we discuss the diagnosis of PMDD and the evidence for the efficacy of fluoxetine and other SSRIs in its treatment.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
